Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
US-2017274073-A1 · Sep 28, 2017 · US
Compositions and methods for treating inflammation and cancer
US12109249B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12109249-B2 |
| Application number | US-201916965797-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 29, 2019 |
| Priority date | Jan 30, 2018 |
| Publication date | Oct 8, 2024 |
| Grant date | Oct 8, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods for the treatment of cancer and/or inflammatory diseases are provided. A combination of interleukin-10 (IL-10) and interleukin-12 (IL-12) is used to treat cancer and/or inflammatory diseases, and a combination of an anti-PD-1 antibody and an anti-IL-17 antibody is used to treat cancer.
First claim
Opening claim text (preview).
We claim: 1. A method of treating a cancer in a subject in need thereof, comprising treating the subject with an anti-PD-1 antibody, measuring a level of IL-17 produced by CD4+ T-cells in the subject, identifying an increase in IL-17 produced by CD4+ T-cells, and administering to the subject a combination of an anti-IL-17 antibody and an anti-PD-1 antibody, wherein the cancer is colon cancer or lung cancer. 2. The method of claim 1 , wherein the cancer is not responsive to treatment with the anti-PD-1 antibody alone. 3. The method of claim 1 , wherein the cancer is lung cancer. 4. The method of claim 1 , wherein the cancer is colon cancer. 5. The method of claim 1 , wherein the combination of the anti-IL-17 antibody and the anti-PD-1 antibody is administered in a singular formulation. 6. The method of claim 1 , wherein the combination of the anti-IL-17 antibody and the anti-PD-1 antibody is administered in separate formulations. 7. The method of claim 1 , wherein the IL-17 measured in the measuring step is IL-17A.
Assignees
Inventors
Classifications
against CD28 or CD152 · CPC title
Interleukins [IL] · CPC title
Comprising a combination of two or more separate antibodies · CPC title
IL-12 · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12109249B2 cover?
- Compositions and methods for the treatment of cancer and/or inflammatory diseases are provided. A combination of interleukin-10 (IL-10) and interleukin-12 (IL-12) is used to treat cancer and/or inflammatory diseases, and a combination of an anti-PD-1 antibody and an anti-IL-17 antibody is used to treat cancer.
- Who is the assignee on this patent?
- Univ Louisville Res Found Inc, Univ Of Louisville Research Foundation
- What technology area does this patent fall under?
- Primary CPC classification A61K38/2066. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).